Study on Mogamulizumab for Treating Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL)

Sponsor: Kyowa Kirin, Inc.

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04745234

Provider View

This clinical trial is testing the safety and tolerability of the drug mogamulizumab, given every four weeks, in adults with certain types of cutaneous T-cell lymphoma (CTCL) that have returned or not responded to previous treatments.

Patient Parameters

Program Overview

This study is designed to evaluate how safe and tolerable the drug mogamulizumab is when given every four weeks to adults with relapsed or refractory mycosis fungoides (MF) and Sézary syndrome (SS), which are subtypes of cutaneous T-cell lymphoma (CTCL). Participants will first undergo a 28-day screening period to determine eligibility, followed by a treatment period that can last up to two years.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of mycosis fungoides (MF) or Sézary syndrome (SS).
  • Be in stage IB, II-A, II-B, III, or IV of the disease.
  • Have tried at least one previous systemic treatment, such as interferon, bexarotene, photopheresis, or chemotherapy. Note: Psoralen plus ultraviolet light therapy (PUVA) is not considered a systemic treatment.

Exclusion Criteria

  • Have current evidence of large cell transformation.
  • Have previously been treated with mogamulizumab.
  • Have a history of receiving an allogeneic transplant.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.